Gilead to pay $40m in HIV drug case settlement
|
Gilead dominates the world market in HIV
pre-exposure prophylaxis (PrEP) with its drug Descovy, based on the molecule
tenofovir alafenamide fumarate ( ... |
Youths 'can lead fight against HIV/AIDS, gender based violence'
The camp included education on sexual and reproductive health, health literacy, HIV , and malaria testing, etc. Adeoye noted the importance of young ... View article...